Maxion Therapeutics

Maxion Therapeutics develops antibody-based biologic drugs using its proprietary KnotBody platform to target ion channels and G-protein-coupled receptors. The company operates from Cambridge and builds therapies for conditions such as chronic pain and autoimmune disorders.